[go: up one dir, main page]

BR0010220A - Compostos de pirimidinona - Google Patents

Compostos de pirimidinona

Info

Publication number
BR0010220A
BR0010220A BR0010220-2A BR0010220A BR0010220A BR 0010220 A BR0010220 A BR 0010220A BR 0010220 A BR0010220 A BR 0010220A BR 0010220 A BR0010220 A BR 0010220A
Authority
BR
Brazil
Prior art keywords
pyrimidinone compounds
pyrimidinone
compounds
pla
atherosclerosis
Prior art date
Application number
BR0010220-2A
Other languages
English (en)
Inventor
Ashley Edward Fenwick
Deirdre Mary Bernadette Hickey
Robert John Ife
Colin Andrew Leach
Ivan Leo Pinto
Stephen Allan Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9910048A external-priority patent/GB9910048D0/en
Priority claimed from GB0002096A external-priority patent/GB0002096D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR0010220A publication Critical patent/BR0010220A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTOS DE PIRIMIDINONA". Compostos Pirimidinona da fórmula (I) são inibidores da enzima Lp-PLA~ 2~ e de uso na terapia, em particular para tratamento de aterosclerose.
BR0010220-2A 1999-05-01 2000-04-25 Compostos de pirimidinona BR0010220A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9910048A GB9910048D0 (en) 1999-05-01 1999-05-01 Novel compounds
GB0002096A GB0002096D0 (en) 2000-01-28 2000-01-28 Novel compounds
PCT/EP2000/003727 WO2000066567A1 (en) 1999-05-01 2000-04-25 Pyrimidinone compounds

Publications (1)

Publication Number Publication Date
BR0010220A true BR0010220A (pt) 2002-05-14

Family

ID=26243514

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010220-2A BR0010220A (pt) 1999-05-01 2000-04-25 Compostos de pirimidinona

Country Status (29)

Country Link
US (2) US6953803B1 (pt)
EP (2) EP1175408B1 (pt)
JP (1) JP2002543190A (pt)
KR (1) KR20020012200A (pt)
CN (1) CN1286822C (pt)
AR (1) AR023777A1 (pt)
AT (2) ATE283845T1 (pt)
AU (1) AU766003B2 (pt)
BR (1) BR0010220A (pt)
CA (1) CA2371671A1 (pt)
CO (1) CO5170521A1 (pt)
CZ (1) CZ20013904A3 (pt)
DE (2) DE60016397T2 (pt)
DK (1) DK1175408T3 (pt)
ES (1) ES2233361T3 (pt)
HK (1) HK1044757B (pt)
HU (1) HUP0201122A3 (pt)
IL (1) IL146210A0 (pt)
MX (1) MXPA01011186A (pt)
MY (1) MY136037A (pt)
NO (1) NO20015329D0 (pt)
NZ (1) NZ515137A (pt)
PE (1) PE20010070A1 (pt)
PL (1) PL351690A1 (pt)
PT (1) PT1175408E (pt)
SI (1) SI1175408T1 (pt)
TR (1) TR200103216T2 (pt)
UY (1) UY26132A1 (pt)
WO (1) WO2000066567A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60016397T2 (de) * 1999-05-01 2005-12-01 Smithkline Beecham P.L.C., Brentford Pyrimidinonverbindung(en)
EP1263740B1 (en) 2000-02-16 2006-07-19 SmithKline Beecham plc Pyrimidine-4-one derivative as ldl-pla2 inhibitor
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127143D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
EP1644353A1 (de) * 2003-07-02 2006-04-12 Bayer HealthCare AG Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
WO2005113797A2 (en) 2004-04-16 2005-12-01 Glaxo Group Limited METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
DE102004061006A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Benzylthio-1,2,4-triazin-5(2H)-one
DE102004061009A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
CN1954826A (zh) * 2005-10-26 2007-05-02 上海生物芯片有限公司 银杏叶提取物在降低胆固醇方面的用途
KR101461659B1 (ko) 2007-05-11 2014-11-17 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
AU2008251467B2 (en) 2007-05-11 2014-07-31 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
UY33388A (es) * 2010-05-17 2011-12-01 Glaxo Group Ltd Nuevos procesos para la preparacion de compuestos de pirimidinona
KR101861883B1 (ko) 2010-12-06 2018-05-28 글락소 그룹 리미티드 Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
CN104478812A (zh) * 2010-12-06 2015-04-01 葛兰素集团有限公司 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
WO2013000108A1 (zh) * 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
CA2842965A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
UY34216A (es) 2011-07-27 2013-02-28 Glaxo Group Ltd Nuevos compuestos que inhiben la actividad de la Lp-PLA2
JP5731718B2 (ja) * 2011-11-11 2015-06-10 ファイザー・インク ２−チオピリミジノン
KR20150111356A (ko) 2013-01-25 2015-10-05 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화합물
AU2014210260B2 (en) 2013-01-25 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2
KR20150108897A (ko) 2013-01-25 2015-09-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 2,3-디히드로이미다졸[1,2-c]피리미딘-5(1h)-온계의 지단백질-연관 포스포리파제 a2 (lp-pla2) 억제제
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US9552473B2 (en) 2014-05-14 2017-01-24 Microsoft Technology Licensing, Llc Claiming data from a virtual whiteboard
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN104840963B (zh) * 2015-05-26 2018-02-16 河北东康生物科技有限公司 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
CN106008362B (zh) * 2016-05-24 2018-08-10 杰达维（上海）医药科技发展有限公司 一种嘧啶衍生物的制备方法
JP6545747B2 (ja) * 2017-05-09 2019-07-17 山田化学工業株式会社 色素化合物
CN112778331B (zh) 2019-11-09 2022-07-05 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1582527A (en) 1975-12-29 1981-01-07 Smith Kline French Lab Pyrimidone and thiopyrimidone derivatives
CA2309177A1 (en) * 1997-11-06 1999-05-20 Stephen Allan Smith Pyrimidinone compounds and pharmaceutical compositions containing them
WO2000010980A1 (en) * 1998-08-21 2000-03-02 Smithkline Beecham Plc Pyrimidinone derivatives for the treatment of atherosclerosis
DE60016397T2 (de) * 1999-05-01 2005-12-01 Smithkline Beecham P.L.C., Brentford Pyrimidinonverbindung(en)

Also Published As

Publication number Publication date
CN1358175A (zh) 2002-07-10
US6953803B1 (en) 2005-10-11
AU766003B2 (en) 2003-10-09
IL146210A0 (en) 2002-07-25
NO20015329L (no) 2001-10-31
TR200103216T2 (tr) 2002-04-22
PE20010070A1 (es) 2001-03-10
KR20020012200A (ko) 2002-02-15
DE60016397D1 (de) 2005-01-05
EP1175408B1 (en) 2004-12-01
EP1175408A1 (en) 2002-01-30
DE60042286D1 (de) 2009-07-09
CA2371671A1 (en) 2000-11-09
CZ20013904A3 (cs) 2002-04-17
HK1044757A1 (en) 2002-11-01
NO20015329D0 (no) 2001-10-31
EP1479671A1 (en) 2004-11-24
HUP0201122A2 (en) 2002-08-28
HK1044757B (zh) 2005-07-08
SI1175408T1 (en) 2005-04-30
HUP0201122A3 (en) 2003-11-28
EP1479671B1 (en) 2009-05-27
PT1175408E (pt) 2005-04-29
ATE283845T1 (de) 2004-12-15
WO2000066567A1 (en) 2000-11-09
NZ515137A (en) 2003-10-31
US7115616B2 (en) 2006-10-03
CO5170521A1 (es) 2002-06-27
AR023777A1 (es) 2002-09-04
JP2002543190A (ja) 2002-12-17
US20040167142A1 (en) 2004-08-26
ATE432265T1 (de) 2009-06-15
MXPA01011186A (es) 2002-08-12
AU4120300A (en) 2000-11-17
UY26132A1 (es) 2000-12-29
MY136037A (en) 2008-08-29
ES2233361T3 (es) 2005-06-16
CN1286822C (zh) 2006-11-29
PL351690A1 (en) 2003-06-02
DE60016397T2 (de) 2005-12-01
DK1175408T3 (da) 2005-04-11

Similar Documents

Publication Publication Date Title
BR0010220A (pt) Compostos de pirimidinona
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
BR0114576A (pt) Composto, composição farmacêutica, uso de um composto, método de tratar um estado doentio e processo para preparar um composto
DK1143967T3 (da) Anticonvulsive derivater egnede til behandling af Hortons hovedpine
BR9713338A (pt) Benzonaftiridinas como terapêuticos brÈnquicos.
TR200103493T2 (tr) Metaloproteaz önleyicileri
TR199901604T2 (xx) Tedavide yararl� kinolin ve kinazolin bile�ikleri.
BR0213994A (pt) Derivados heterocìclicos de glicinamida e seus usos médicos
IL122737A0 (en) Salts of amidine derivative and cyclooxygenase inhibitors their preparation and pharmaceutical compositions containing them
TR200102131T2 (tr) Matrisk metaloproteinaz inhitörleri olarak 2,3,4,5-tetrahidro-1H[1,4] benzodiyazepin-3- hidroksamik asitler.
YU68900A (sh) Kombinacije inhibitora protein farnesiltransferaze i hmg coa reduktaze i njihova upotreba u tretmanu raka
NO980923L (no) Optisk aktivt fenylpyrimidin-derivat som analgetisk middel
GB2324091B (en) Metalloproteinase inhibitors
DK1015437T3 (da) Benzoxazin- og benzothiazin-derivater og deres anvendelse i lægemidler
BR0114884A (pt) Compostos calcilìticos
DK1244643T3 (da) Tryptaseinhibitorer
PT1244614E (pt) Inibidores de triptase
BR9813897A (pt) Derivados de bifenila como farmacêuticos
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
PT1232173E (pt) Derivados do acido fusidico
DK0937075T3 (da) Hidtil ukendte imidazo- og oxazolopyridiner som phosphodiesteraseinhibitorer
ECSP003440A (es) Nuevos compuestos de pirimidinona y procedimiento
AU758194C (en) Novel benzimidazoles and benzoxazoles
UY26102A1 (es) Derivados de 1-aminoetilindol, su preparación y su aplicación en terapéutica
ECSP961804A (es) Nuevos compuestos monociclicos de b -.lactama

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.